- conflicts or gaps
- [[{"field": "founded_year", "conflict": {"value": "2017 reported by Tracxn, Pharmaletter, LinkedIn vs 2018 on YC profile and company materials", "source_urls": ["https://tracxn.com/d/companies/abalonebio/__hBHogtI_6guPUh605YtYjb0ktNfA5oxPScZ_HK-RPFg", "https://www.thepharmaletter.com/abalone-bio", "https://www.ycombinator.com/companies/abalone-bio"]}}, {"field": "hq_location", "conflict": {"value": "Emeryville (SBIR filings, press releases) vs San Francisco (YC) vs Richmond (YCDB, Tracxn)", "source_urls": ["https://www.sbir.gov/portfolio/1311503", "https://www.ycombinator.com/companies/abalone-bio", "https://www.ycdb.co/company/abalone-bio", "https://tracxn.com/d/companies/abalonebio/__hBHogtI_6guPUh605YtYjb0ktNfA5oxPScZ_HK-RPFg"]}}, {"field": "headcount", "conflict": {"value": "14 (YC, LinkedIn) vs 12 (SBIR gov filing) vs 21 (GetLatka); no single authoritative current count", "source_urls": ["https://www.ycombinator.com/companies/abalone-bio", "https://www.linkedin.com/company/abalone-bio-inc", "https://www.sbir.gov/portfolio/1311503", "https://getlatka.com/companies/abalonebio.com"]}}, {"field": "equity_funding_total", "conflict": {"value": "Tracxn reports $125K total equity; Startup Intros reports $150K seed round; YC standard deal is $125K; unclear if these are same or separate rounds", "source_urls": ["https://tracxn.com/d/companies/abalonebio/__hBHogtI_6guPUh605YtYjb0ktNfA5oxPScZ_HK-RPFg/funding-and-investors", "https://startupintros.com/news/2020-03-01-abalone-bio-seed", "https://www.ycombinator.com/companies/abalone-bio"]}}, {"field": "grant_funding_total", "conflict": {"value": "YC claims $7M non-dilutive grants vs SBIR.gov official total $6,595,424 across 9 awards; Startup Intros also cites $7M SBIR", "source_urls": ["https://www.ycombinator.com/companies/abalone-bio", "https://www.sbir.gov/portfolio/1311503", "https://startupintros.com/orgs/abalone-bio"]}}, {"field": "partnership_count", "conflict": {"value": "YC profile cites 3 partnerships with $3M revenue; public press releases show at least 4 named partners (Pfizer, Sihuan, UPenn, Mount Sinai) as of 2026", "source_urls": ["https://www.ycombinator.com/companies/abalone-bio", "https://www.einpresswire.com/article/876655975/abalone-bio-and-pfizer-launch-research-collaboration-to-discover-gpcr-modulating-antibodies", "https://www.einpresswire.com/article/862766837/abalone-bio-sihuan-pharmaceutical-launch-collaboration-to-develop-a-novel-obesity-drug"]}}, {"field": "revenue", "conflict": {"value": "GetLatka claims $5M ARR in 2024 and bootstrapped/no outside funding, contradicting YC partnership revenue claims and documented VC/grant funding", "source_urls": ["https://getlatka.com/companies/abalonebio.com", "https://www.ycombinator.com/companies/abalone-bio"]}}, {"field": "lead_program_indication", "conflict": {"value": "ABt140 referenced for CIPN (SBIR Phase II), endometriosis (SBIR Phase I), and liver fibrosis (Phase II liver program); primary lead indication not officially ranked", "source_urls": ["https://www.sbir.gov/portfolio/1311503", "https://www.sbir.gov/awards/193582"]}}, {"field": "clinical_stage", "gap": {"value": "No public evidence of IND filing or clinical trials; company and SBIR materials describe preclinical/IND-enabling stage only", "source_urls": ["https://www.abalonebio.com/pipeline", "https://www.sbir.gov/portfolio/1311503"]}}, {"field": "total_raised_usd", "gap": {"value": "No single audited total combining equity, grants, and partnership upfronts publicly disclosed; third-party databases disagree materially", "source_urls": ["https://tracxn.com/d/companies/abalonebio/__hBHogtI_6guPUh605YtYjb0ktNfA5oxPScZ_HK-RPFg", "https://www.sbir.gov/portfolio/1311503", "https://getlatka.com/companies/abalonebio.com"]}}]]
- source urls
- ["https://getlatka.com/companies/abalonebio.com", "https://nsf.elsevierpure.com/en/projects/sbir-phase-i-a-platform-for-identifying-antibodies-that-modulate-/", "https://startupintros.com/news/2020-03-01-abalone-bio-seed", "https://startupintros.com/orgs/abalone-bio", "https://tracxn.com/d/companies/abalonebio/__hBHogtI_6guPUh605YtYjb0ktNfA5oxPScZ_HK-RPFg", "https://tracxn.com/d/companies/abalonebio/__hBHogtI_6guPUh605YtYjb0ktNfA5oxPScZ_HK-RPFg/funding-and-investors", "https://www.abalonebio.com/", "https://www.abalonebio.com/about", "https://www.abalonebio.com/pipeline", "https://www.abalonebio.com/platform", "https://www.calaverasenterprise.com/articles/news/woman-on-mission-to-improve-ski-safety-standards-after-death-of-husband/", "https://www.einpresswire.com/article/790617405/abalone-bio-and-university-of-pennsylvania-announce-collaboration-to-develop-next-generation-obesity-drugs", "https://www.einpresswire.com/article/837016540/abalone-bio-and-mount-sinai-publish-preclinical-data-on-world-s-first-cb2-antibody-agonists", "https://www.einpresswire.com/article/862766837/abalone-bio-sihuan-pharmaceutical-launch-collaboration-to-develop-a-novel-obesity-drug", "https://www.einpresswire.com/article/876655975/abalone-bio-and-pfizer-launch-research-collaboration-to-discover-gpcr-modulating-antibodies", "https://www.linkedin.com/company/abalone-bio-inc", "https://www.linkedin.com/in/richard-c-yu", "https://www.sbir.gov/awards/193582", "https://www.sbir.gov/awards/200902", "https://www.sbir.gov/awards/213245", "https://www.sbir.gov/portfolio/1311503", "https://www.thepharmaletter.com/abalone-bio", "https://www.ycdb.co/company/abalone-bio", "https://www.ycombinator.com/companies/abalone-bio", "https://yc-oss.github.io/api/batches/winter-2020/abalone-bio.json"]